[go: up one dir, main page]

UA93284C2 - Поліетиленгліколь-g-csf кон'югат - Google Patents

Поліетиленгліколь-g-csf кон'югат

Info

Publication number
UA93284C2
UA93284C2 UAA200904695A UAA200904695A UA93284C2 UA 93284 C2 UA93284 C2 UA 93284C2 UA A200904695 A UAA200904695 A UA A200904695A UA A200904695 A UAA200904695 A UA A200904695A UA 93284 C2 UA93284 C2 UA 93284C2
Authority
UA
Ukraine
Prior art keywords
peg
csp
conjugate
mol
branched
Prior art date
Application number
UAA200904695A
Other languages
English (en)
Russian (ru)
Inventor
Єонг-Ву Йо
Вун-Йонг Йоо
Хьюн-Кюю Джеон
Юн-Кюю Чоі
Хіе-Ін Янг
Вьонг-Мун Кім
Сунг-Хі Лі
Су-Хьюнг Канг
Му-Хі Йоо
Original Assignee
Донг-А Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Донг-А Фарм. Ко., Лтд. filed Critical Донг-А Фарм. Ко., Лтд.
Publication of UA93284C2 publication Critical patent/UA93284C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Даний винахід стосується кон'югата триланцюгового PEG-G-CSF загальної формули (1), де відношення зв'язування триланцюгового поліетиленгліколю (PEG) та G-CSF становить 1:1 (мол/мол), a PEG має середню молекулярну масу від 200 до 45,000 дальтон; фармацевтичної композиції, що його містить, та способу його одержання. EMBED ISISServer (1)
UAA200904695A 2006-11-17 2006-11-22 Поліетиленгліколь-g-csf кон'югат UA93284C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060113721A KR101079993B1 (ko) 2006-11-17 2006-11-17 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
PCT/KR2006/004908 WO2008060002A1 (en) 2006-11-17 2006-11-22 Polyethylene glycol-g-csf conjugate

Publications (1)

Publication Number Publication Date
UA93284C2 true UA93284C2 (uk) 2011-01-25

Family

ID=39401799

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200904695A UA93284C2 (uk) 2006-11-17 2006-11-22 Поліетиленгліколь-g-csf кон'югат

Country Status (13)

Country Link
US (1) US8329191B2 (uk)
EP (1) EP2081580B1 (uk)
JP (1) JP5363987B2 (uk)
KR (1) KR101079993B1 (uk)
CN (1) CN101616678B (uk)
AU (1) AU2006350790B2 (uk)
BR (1) BRPI0622128A2 (uk)
ES (1) ES2433253T3 (uk)
MX (1) MX2009005205A (uk)
PL (1) PL2081580T3 (uk)
RU (1) RU2423133C2 (uk)
UA (1) UA93284C2 (uk)
WO (1) WO2008060002A1 (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5589503B2 (ja) * 2009-03-31 2014-09-17 日油株式会社 多分岐鎖ポリオキシアルキレン化合物、その製造方法および中間体
DK2947111T3 (en) * 2013-01-17 2018-05-07 Xiamen Sinopeg Biotech Co Ltd MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME
US9319147B2 (en) 2014-06-30 2016-04-19 Alcatel Lucent Optical receiver for quadrature-phase-shift-keying and quadrature-duobinary signals
CN108368162B (zh) * 2016-04-15 2021-11-12 江苏恒瑞医药股份有限公司 一种重组人粒细胞刺激因子的复性及纯化方法
WO2018227142A1 (en) * 2017-06-09 2018-12-13 The Regents Of The University Of Colorado, A Body Corporate Gm-csf mimetics and methods of making and using same
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
US10882954B2 (en) 2019-04-11 2021-01-05 Sunbio Inc. Tertiary alkoxy polyethylene glycol and derivatives thereof
KR20230045586A (ko) * 2021-09-28 2023-04-04 한양대학교 산학협력단 암 치료용 글리시리진-분지형 폴리에틸렌글리콜 컨쥬게이트

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
BR0007781A (pt) 1999-01-29 2002-02-05 Hoffmann La Roche Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
CN1321134C (zh) * 2000-11-23 2007-06-13 赵剑 一种生物活性蛋白质的非均一制品及其制备方法
CN1176137C (zh) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
KR100508358B1 (ko) 2002-03-20 2005-08-17 주식회사 바이오폴리메드 생체적합성 고분자가 시스테인 잔기에 화학양론적으로 결합된 ｇ-ｃｓｆ의 제조 방법
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
KR20040083268A (ko) * 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
KR101237884B1 (ko) * 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
EP1789092A2 (en) 2004-08-31 2007-05-30 Pharmacia & Upjohn Company LLC Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof

Also Published As

Publication number Publication date
AU2006350790B2 (en) 2010-04-29
JP2010510204A (ja) 2010-04-02
US20100105616A1 (en) 2010-04-29
PL2081580T3 (pl) 2014-01-31
RU2423133C2 (ru) 2011-07-10
US8329191B2 (en) 2012-12-11
KR101079993B1 (ko) 2011-11-04
EP2081580B1 (en) 2013-08-14
EP2081580A4 (en) 2011-08-10
AU2006350790A1 (en) 2008-05-22
CN101616678A (zh) 2009-12-30
ES2433253T3 (es) 2013-12-10
RU2009122976A (ru) 2010-12-27
EP2081580A1 (en) 2009-07-29
KR20080044639A (ko) 2008-05-21
HK1138799A1 (en) 2010-09-03
BRPI0622128A2 (pt) 2011-12-27
JP5363987B2 (ja) 2013-12-11
WO2008060002A1 (en) 2008-05-22
CN101616678B (zh) 2012-10-03
MX2009005205A (es) 2009-05-28

Similar Documents

Publication Publication Date Title
MXPA05003394A (es) Conjugados de polimero con antigenicidad disminuida, metodos de preparacion y usos de estos.
MX2012000369A (es) Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion.
EP2261236A3 (en) Composition for proteasome inhibition
WO2006005058A3 (en) Polymer-factor ix moiety conjugates
EP1604989A8 (en) DPP-IV inhibitors
IL229304A (en) Compounds 1 ', 3' - Imaging Converts - 4 - Phenyl - 3, 4, 5, 6 - Tetrahydro - 2h, 1'h, [1, 4 '] Bipyridinyl - 2' - lozenges, pharmaceutical preparations containing them and their use
NZ597912A (en) Pegylated l-asparaginase
WO2008024435A3 (en) Dendritic molecular intracellular transporters and methods of making and using same
PL1758553T3 (pl) Kompozycje farmaceutyczne zawierające glikol polietylenowy o masie cząsteczkowej niższej niż 600 Daltonów
MXPA03008886A (es) Composiciones de baja respuesta glicemica.
WO2007019331A3 (en) Conjugates of a g-csf moiety and a polymer
EP2679244A3 (en) Formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2004050058A3 (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP2279758A3 (en) Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
EP3895699A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof
TW200745221A (en) Novel use of a copolymer comprising polyamide blocks and polyether blocks originating at least partially from polytrimethylene ether glycol
WO2010138544A3 (en) Oral care formulations that enhance amount of soluble zinc
EP1598341A8 (en) DPP-IV inhibitors
WO2004113297A3 (en) Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1604980A8 (en) DPP-IV inhibitors
UA93284C2 (uk) Поліетиленгліколь-g-csf кон'югат
WO2008088624A3 (en) Hydroxyl-terminated or carboxylic acid- terminated reactive monomer compositions, their preparation and their use
WO2012059725A8 (en) Peg or peg block copolymers for treating colorectal cancer
MX2009007543A (es) Conjugados de polimero de posaconazol y metodos de tratamiento usando los conjugados de posaconazol y polimero.